Loading…
PYPD
PolyPid Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP M8001Q126
$5.07-0.98%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $102.98M
- P/E
- —
- Forward P/E
- —
- P/B
- 19.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.30
- ROE
- -243.59%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.39
- 52-week high
- $5.73
- 52-week low
- $3.06
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.6% over 5Y.
today you would have $22.37▼ -97.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $4.34 | $3.04 | $3.80 | $20.94 | $172.20 | $297.00 | |
| P/E | 1.3x | 2.1x | 0.6x | 0.2x | 0.3x | 2.5x | 2.2x |
| P/B | 3.0x | 7.2x | 4.0x | — | 2.4x | 3.0x | 2.5x |
| EPS | $2.09 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLYXPolaryx Therapeutics, Inc. | $2.06 | — | 9.4x | — | -96.56% | $102.68M |
| CRDFCardiff Oncology, Inc. | $1.33 | — | 3.4x | — | -94.08% | $103.47M |
| LNSRLENSAR, Inc. | $8.30 | 41.5x | 6.8x | — | 357.30% | $101.97M |
| CCLDCareCloud, Inc. | $2.49 |
About the company
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
- 69
- Petah Tikva, Israel
Company description provided by Yahoo Finance.